

Drug Development Challenges. Facilitating collaboration.



Charlene Reed, PhD, CEO

Then



Now



Global Pandemic

Margaret Chan, the World Health Organization's director-general told a meeting in Copenhagen in March of 2012:

“If the current trends continue unabated, the future is easy to predict. This will be a post-antibiotic era. In terms of new replacement antibiotics, the pipeline is virtually dry.”

The FCAR

A microscopic view of cells, showing several clusters of spherical cells with textured surfaces. The background is a soft, blue-tinted gradient. The cells are rendered in a 3D style, giving them a realistic appearance.

Our mission is to facilitate
the **discovery and the
development of therapies**
to fight this global
pandemic.

Success

- * Accelerated discovery, development and regulatory approval of new therapies for antibiotic-resistant microbes
- * Equitable global access to those therapies
- * Global awareness and advocacy for antimicrobial resistance

Complex problem

- * Scientifically
- * Clinically
- * Financially
- * Socially

Scientific

- * Traditional HTS mostly fail to identify compounds that inhibit bacterial targets because by design industry's compound collections are biased toward mammalian targets
- * Mammalian targets are a wide range of proteins
- * Bacterial targets are intracellular proteins and inhibitors of those enzymes likely occupy a different physiochemical space

Financial

- * Industry commitment
 - * The business model for antimicrobials needs to be rethought/reworked
- * Philanthropic commitment
- * Government investments
- * Product development partnerships

Social

- * Public awareness
 - * Resistance
 - * Infection
 - * Value of Antibiotics

Clinical Development

- * Create more favorable environment for drug development
- * Overcome obstacles standing in the way to new therapies
- * Regulatory guidelines must evolve to support the development paradigm
- * Focus on regulatory pathways and tools to support development

Collaborative Coordinating Structure



Unprecedented opportunity

- * Work together to keep up the momentum
- * Develop the regulatory science and infrastructure needed for this global unmet medical need.

The FCAR

- * We are motivated by the victims of antimicrobial drug resistance



- * We are dedicated to ensuring that new therapies are developed, adopted, accessible and affordable